Benzinga | Sep 15, 2021 04:02PM EDT

Crinetics Pharmaceuticals' Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept With Strong Dose-dependent Suppression Of Insulin Secretion In Phase 1 Single Ascending Dose Study

CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms



Demonstrated Dose-dependent Reductions in Glucose-stimulated and Sulfonylurea-induced Insulin Secretion

Management Hosting Webcast to Discuss Findings Today at 4:30 p.m. Eastern Time